Effects of a Supervised Rehabilitation Program on Disease Severity in Spastic Ataxias

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age16+
SponsorLaval University

About this trial

Spastic ataxias are a group of diseases causing symptoms such as walking difficulties and balance impairments that lead to a high risk of falls. No pharmacological treatments exist to treat these diseases. Unfortunately, little effort is made to develop non-pharmacological treatments specific to spastic ataxias despite the detrimental impact of the disease on several aspects of an individual's life and the high cost of falls for society each year. The three objectives of this project are: 1) to determine the effect of a 12-week rehabilitation program on disease severity as compared with usual care for individuals with spastic ataxias; 2) to identify which factors can help (or not) the implementation of the program in the clinical settings ("reel world"); and 3) to explore the cost-benefits of IMPACT \[rehabIlitation prograM for sPAstiC aTaxias\]. The team has developed the program to specifically target symptoms present in these patients and was previously pilot-tested. Based on the results obtained in this pilot project, positive effects are expected concerning the disease severity of participants. The investigators want, with this project, provide to health care professionals an option to offer better-suited services to people living with spastic ataxia worldwide.

Eligibility criteria

Qualifiers

have a confirmed genetic diagnosis of ARSACS or SPG7

be able to maintain standing position and to transfert

be authorized by their treating neurologist

speak French or English

Disqualifiers

have active participation in a rehabilitation program (self-reported information)

have another condition causing physical limitations

be uncomfortable in a swimming pool

be pregnant.

Trial design

Treatments tested in this trial

  • IMPACT - rehabIlitation prograM for sPAstiC aTaxias

Treatment groups

84 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Laval University

Lead sponsor

McGill University

Collaborator

Université de Sherbrooke

Collaborator

Université du Québec a Montréal

Collaborator

University of Calgary

Collaborator

Corporation de recherche et d'action sur les maladies héréditaires (CORAMH)

Collaborator

Cégep de Jonquière

Collaborator

Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-St-Jean

Collaborator

Muscular Dystrophy Canada

Collaborator

University of Alberta

Collaborator

Integrated University Health and Social Services Center of the Capitale-Nationale

Collaborator